Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it expects double-digit revenue and core profit ...

March has officially arrived, which means Spring is finally just around the corner. When it comes to swapping one’s wardrobe ...

The Oscars after-party was held at the Wallis Annenberg Center for the Performing Arts in Beverly Hills. The star-studded ...

Some local governments across the state of West Virginia are cracking down on the regulations around beekeeping. Across the ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

In this article, we will take a look into Eli Lilly and Co's (NYSE:LLY) DCF analysis, a reliable and data-driven approach to ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lone Pine Capital. In this article, we are going to take ...

More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an ...

Pfizer CEO Albert Bourla on Monday said that the company might move overseas manufacturing to its existing plants in the ...

People who land in the ER after using hallucinogens are more than twice as likely to die in a handful of years, a new study ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.